



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

March 11, 2014 6:00 – 8:15 p.m.

***** Please note new times *****

- 1. Executive Session** **6:00 - 6:15**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:15 - 6:20**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:20 - 6:25**
 - Updates

- 4. Medical Director Update** **6:25 - 6:30**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:30 – 7:00**
 - Oxycodone IR/Hydromorphone IR Retrospective Drug Utilization Review

- 6. RetroDUR/DUR** **7:00 – 7:00**
 - No new topics this meeting

- 7. Therapeutic Drug Classes – Periodic Review** **7:00 – 7:10**
(Public comment prior to Board action)
 - Hepatitis C Medications

- 8. Clinical Update: Drug Reviews** **7:10 – 8:05**
(Public comment prior to Board action)
 - New to Market**
 - Zohydro[®] ER (hydrocodone) – update
 - Abbreviated New Drug Reviews**
 - Epaned[®] (enalapril) Oral Solution
 - Esomeprazole[®] (esomeprazole) Oral Capsule
 - Onfi[®] (clobazam) Oral Suspension
 - Simponi[®] (golimumab) IV Infusion (Rheumatoid Arthritis)
 - Simponi[®] (golimumab) Subcutaneous (100 mg dose for Ulcerative Colitis)
 - Trokendi[®] XR (topiramate) Extended Release Oral Capsule

- Full New Drug Reviews**
- Brisdelle[®] (paroxetine) Oral Capsule
 - Mirvaso[®] (brimonidine) Topical Gel
 - Olysio[®] (simeprevir) Oral Capsule (updated with new AASLD guidelines)
 - Sovaldi[®] (sofosbuvir) Oral Tablet (updated with new AASLD guidelines)
- 9. Clinical Update: New/Updated Clinical Guidelines** **8:05 – 8:10**
(Public comment prior to Board action)
- American Academy of Neurology (AAN) Guidelines on Stroke Prevention in Nonvalvular Atrial Fibrillation (NVAf)
- 10. New Managed Therapeutic Drug Classes** **8:10– 8:10**
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:10 – 8:10**
(Public comment prior to Board action)
- None
- 12. General Announcements** **8:10– 8:15**
Selected FDA Safety Alerts
- FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza[®] and Kombiglyze[®] XR)
 - FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products
- 13. Adjourn** **8:15**